Belite Bio (BLTE) Depreciation & Amortization (CF) (2024 - 2025)
Belite Bio (BLTE) posted quarterly Depreciation & Amortization (CF) of $45000.0 for Q4 2025, up 4.65% year-over-year from $43000.0 in Q4 2024, and up 4.65% quarter-over-quarter from $43000.0 in Q4 2024.
Belite Bio (BLTE) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends
Belite Bio's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $45000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 4.65% year-over-year to $45000.0; the TTM figure through Mar 2026 stood at $45000.0 (up 4.65% YoY), while the FY2025 annual figure was $464000.0, up 3.34% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $45000.0, up from $43000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $45000.0 in Q4 2025, with the low at $43000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Dec 31, 2024 | 43,000.00 |